10-Q: Bausch + Lomb Reports First Quarter 2024 Results, Revenue Up 18% Year-Over-Year

Bausch + Lomb's first quarter 2024 results show a significant revenue increase of 18% compared to the same period last year, driven by acquisitions and volume growth.

Summary

• Bausch + Lomb reported a net loss of $167 million for the first quarter of 2024, compared to a net loss of $90 million in the same period of 2023.
• The company's revenue increased by 18% year-over-year, reaching $1.099 billion, driven by acquisitions, increased volumes, and net realized pricing.
• The Vision Care segment saw an 8% revenue increase, while the Pharmaceuticals segment experienced a 66% surge, and the Surgical segment grew by 8%.
• Cost of goods sold increased by 14% to $423 million, and selling, general, and administrative expenses rose by 21% to $504 million.
• The company's operating income was $6 million, a significant improvement from the operating loss of $2 million in the first quarter of 2023.
• Interest expense increased to $99 million, up from $50 million in the prior year, due to new debt facilities.
• The provision for income taxes was $73 million, compared to $33 million in the first quarter of 2023.
• The company's cash and cash equivalents and restricted cash decreased to $325 million from $334 million at the beginning of the period.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong, the net loss and increased expenses temper the positive aspects. The company is making strategic moves, but faces challenges with debt and market conditions.

Positives

• The company experienced significant revenue growth across all segments, particularly in Pharmaceuticals.
• Operating income improved compared to the same period last year.
• The company has a robust pipeline of over 60 projects in various stages of development.
• The company has made strategic acquisitions, including XIIDRA and the Blink product line, to enhance its portfolio.

Negatives

• The company reported a net loss of $167 million for the quarter.
• Interest expense increased significantly due to new debt facilities.
• The provision for income taxes increased by $40 million compared to the same period last year.
• The company's cash and cash equivalents and restricted cash decreased by $9 million during the quarter.

Risks

• The company faces risks associated with the ongoing conflict between Russia and Ukraine and in the Middle East involving Israel and Hamas.
• The company is subject to ongoing litigation and potential additional litigation related to the B+L IPO and the proposed separation from BHC.
• The company faces risks related to generic competition and loss of exclusivity for certain products.
• The company is subject to ongoing oversight and review by regulatory and governmental agencies.
• The company's ability to comply with financial covenants in debt agreements could be impacted by market conditions.

Future Outlook

The company plans to develop and commercialize its global pipeline of over 60 projects, including new contact lenses for myopia, next-generation cataract equipment, premium IOLs, investigational treatments for dry eye, novel formulation for eye vitamins and preservative free formulation of eye drops.

Industry Context

The company's performance reflects the ongoing trends in the eye health industry, including the demand for innovative products and treatments for various eye conditions. The company's strategic acquisitions and focus on R&D are aligned with the industry's growth trajectory.

Comparison to Industry Standards

• Bausch + Lomb's revenue growth of 18% is strong compared to the average growth rate of the medical device and pharmaceutical industry, which is typically in the single-digit range.
• The company's performance in the Pharmaceuticals segment, with a 66% revenue increase, is particularly notable and suggests a successful integration of the XIIDRA acquisition.
• The company's operating income improvement indicates progress in managing costs, but the net loss highlights the impact of increased interest expenses and taxes.
• Compared to competitors like Alcon and Johnson & Johnson Vision, Bausch + Lomb's focus on both pharmaceutical and surgical segments provides a diversified revenue stream.

Legal Proceedings

• The company is involved in various legal and administrative proceedings, including product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations.
• The company is a defendant in multidistrict antitrust litigation related to generic pharmaceutical pricing.
• The company is involved in product liability lawsuits related to Shower to Shower body powder.
• The company is involved in a declaratory judgment action in New Jersey related to alleged transfers of assets from BHC.
• The company is involved in a lawsuit with Doctors Allergy Formula, LLC related to a 2015 Asset Purchase Agreement.
• The company is involved in patent infringement proceedings related to PreserVision AREDS and Lumify products.

Related Party Transactions

• Certain transactions between Bausch + Lomb and BHC and affiliate businesses are cash-settled on a current basis.
• Amounts payable to BHC and its affiliates related to related party transactions were $51 million as of March 31, 2024.
• Amounts due from BHC and its affiliates related to related party transactions were $59 million as of March 31, 2024.
• The company has entered into various agreements with BHC, including a Transition Services Agreement, Tax Matters Agreement, and Employee Matters Agreement.

Stakeholder Impact

• Shareholders may be concerned about the net loss, but encouraged by the revenue growth and strategic initiatives.
• Employees may be affected by restructuring and integration costs, but also benefit from the company's growth and development.
• Customers may benefit from the company's expanded product portfolio and new product launches.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may be concerned about the company's increased debt, but reassured by its revenue growth and ability to meet debt service obligations.

Next Steps

• The company plans to launch its SiHy Daily lenses into additional countries throughout 2024.
• The company anticipates launching Blink NutriTears during the third quarter of 2024.
• The company expects approval for MIEBO in Canada during 2024.
• The company plans to launch LuxLife Trifocal IOL in various European markets in 2025.
• The company anticipates launching enVista Aspire in Europe and Canada in 2025.
• The company anticipates launching enVista Envy in the U.S. and Canada in 2024, and in Europe in 2025.
• The company anticipates launching enVista Beyond in the U.S. in 2026.

Key Dates

Keywords

Bausch + Lomb, revenue, financial results, ophthalmology, XIIDRA, MIEBO, Vision Care, Pharmaceuticals, Surgical, debt, acquisitions, net loss, operating income, credit facilities, share-based compensation